In summary: BPC-157 is a promising compound for different cytoprotective uses It is not FDA approved for human use There is not some shadow cabal blocking the use of BPC-157 - Financial incentives make it so that BPC-157 is challenging to push through the regulatory process - It will likely never receive FDA approval, but will be available in some form as oral supplement or through compounding pharmacies, with some modification This is not medical advice
The data in Figure 24 confirm this expectation by demonstrating that D-Nle-Cys-Ile-NH-(CH 2 )5-CONH 2 and D-Nle-Tyr-Ile-NH-(CH 2 ) 5 -CONH 2 , which bind HGF with high affinity (Figure 23) and effectively attenuate HGF-dependent processes (Figures 25, 26, 27 ) completely block HGF dimer formation
This cuts total time to 6 months versus the standard 9 months
Use is restricted to trained professionals operating in laboratory or research settings, following appropriate safety and handling protocols.
(Olympus BX51, Tokyo, Japan
Protocol themes: People frequently mention once-daily evening dosing , though patterns vary by provider
